Pfizer is expected to report its third-quarter results next month, and analysts are projecting a double-digit decline in its ...

After a muted start to 2025, Big Pharma is back on the M&A trail. In just a month, three major players — Pfizer PFE, Novo ...

US healthcare st‌ocks have been u⁠nder moun⁠ting pressure this year, largel⁠y⁠ due to po‍licies​ introduce‌d b‍y the Tr​u‌m‍p ...

Fintel reports that on October 15, 2025, Goldman Sachs downgraded their outlook for Arvinas (NasdaqGS:ARVN) from Neutral to ...

What's the most attractive biotech stock right now for investors? Seeking Alpha analysts ONeil Trader and Terry Chrisomalis ...

During periods of economic uncertainty, investing in pharmaceutical companies demonstrates unique defensive characteristics.

Detailed price information for Akebia Therapeutics (AKBA-Q) from The Globe and Mail including charting and trades.

You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. Is the market rally running out of steam? On Trader Talk, veteran market technician Mark Newton of ...

Read here for an update on how to build a simple, diversified 6-fund retirement portfolio for steady income, growth, and ...

This sustained sell-off has wiped out approximately $18 billion in market capitalization, leaving its current value at around ...

Pfizer's revenue has stabilized, and a recent drug pricing deal with the US government reduces political uncertainty. Find ...

President Donald Trump said there will be lower prices for Ozempic after negotiations with Novo Nordisk as part of his ...